FOXO Technologies Receives Notice From NYSE American Regarding Late Filing Of Quarterly Report On Form 10-Q

FOXO Technologies Inc. Class A Common Stock -5.35%

FOXO Technologies Inc. Class A Common Stock




FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company"), a leader in the field of epigenetic biomarker technology, announced that on November 21, 2023, it received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American (the "Exchange") under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide (the "Company Guide"). The non-compliance results from the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Delinquent Report") by the filing due date of November 20, 2023 (the "Filing Delinquency").

In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency, or until May 20, 2024 (the "Initial Cure Period"), to file the Form 10-Q with the SEC. If the Company fails to file the Form 10-Q during the Initial Cure Period, the Exchange may, in its sole discretion, provide an additional six-month cure period (the "Additional Cure Period"). The Company can regain compliance with the Exchange's continued listing standards at any time during the Initial Cure Period or Additional Cure Period, as applicable, by filing the Form 10-Q and any subsequent delayed filings with the SEC.

The Company filed its Annual Report on Form 10-K with the SEC on March 30, 2023, and expects to file its Form 10-Q as soon as practicable.

During the Initial Cure Period and the Additional Cure Period, if applicable, the Company's securities will continue to trade on the Exchange, subject to the Company's compliance with other continued listing requirements, with a late filer (".LF") indicator.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via